Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review

Journal of the American Academy of Dermatology

Volumn 61, Issue 3, 2009, Pages 486-504

  Moustou, Aikaterini Evaggelia ^a   Matekovits, Athina ^a   Dessinioti, Clio ^a   Antoniou, Christina ^a   Sfikakis, Petros P ^a   Stratigos, Alexander J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRALGIA; AUTOIMMUNE SKIN DISEASE; BACTERIAL INFECTION; BIOLOGICAL THERAPY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; ECZEMA; FACE EDEMA; FATIGUE; GRANULOMA ANNULARE; GRANULOMATOSIS; HEADACHE; HERPES VIRUS INFECTION; HUMAN; INFECTION; INJECTION SITE REACTION; KERATOACANTHOMA; LARGE CELL LYMPHOMA; LICHENOID; LUPUS ERYTHEMATOSUS; LUPUS VULGARIS; LYMPHOMA; MELANOCYTIC NEVUS; MELANOMA; MYALGIA; MYCOBACTERIOSIS; MYCOSIS; NEOPLASM; NONHUMAN; PAPULOPUSTULAR ERUPTION; PRIORITY JOURNAL; PSORIASIS; PUBLICATION; REVIEW; RHEUMATOID ARTHRITIS; SEZARY SYNDROME; SKIN CANCER; SKIN INFECTION; SKIN LYMPHOMA; URTICARIA; VASCULITIS;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL THERAPY; DRUG ERUPTIONS; HUMANS; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68849111338     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.10.060     Document Type: Review

References (164)

1. Beulter B., and Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 7 (1989) 625-655
2. Aggarwal B.B., Moffat B., and Harkins R.N. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 259 (1984) 686-691
3. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10 (1992) 411-453
4. Murray K.M., and Dahl S.L. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 31 (1997) 1335-1338
5. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30 (1993) 1443-1453
6. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 58 Suppl. 1 (1999) I70-I72
7. Scallon B.J., Moore M.A., Trinh H., Knight D.M., and Ghrayeb J. Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
8. Hanauer S.B. Safety of infliximab in clinical trials. Pharmacol Ther 13 suppl 4 (1999) 16-21
9. Harriman G., Harper L.K., and Schaible J.D. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF-alpha treatment. Ann Rheum Dis 58 (1999) 161-164
10. Klareskog L., Moreland L., Cohen S., Sanda M., and Burge D. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy in rheumatoid arthritis. Arthritis Rheum 44 (2001) S77
11. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
12. Tutrone W.D., Saini R., and Weinberg J.M. Biological therapy for psoriasis: an overview of infliximab, etanercept and alefacept. IDrugs 7 (2004) 45-49
13. Isaacs J.D. The antiglobulin response to therapeutic antibodies. Semin Immunol 2 (1990) 449-456
14. Cheifetz A., and Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72 (2005) 250-256
15. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
16. Thielen A.M., Kuenzli S., and Saurat J.H. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 211 (2005) 209-217
17. Persley K.M. Infliximab infusion reactions: desensitizing ourselves to the danger. Inflamm Bowel Dis 10 (2004) 62-63
18. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003) 1315-1324
19. Lequerré T., Vittecoq O., Klemmer N., Goëb V., Pouplin S., Menard J.F., et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 33 (2006) 1307-1314
20. Han P.D., and Cohen R.D. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 64 (2004) 1767-1777
21. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 711-715
22. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56 (2007) 31.e1-15
23. Lobel E.Z., Korelitz B.I., and Warman J.I. Red man syndrome and infliximab. J Clin Gastroenterol 36 (2003) 186
24. Augustsson J., Eksborg S., Ernestam S., Gullström E., and van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 1462-1466
25. Werth V.P., and Levinson A.I. Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunochemistry. Arch Dermatol 137 (2001) 953-955
26. Youdim A., Vasiliauskas E.A., Targan S.R., Papadakis K.A., Ippoliti A., Dubinsky M.C., et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10 (2004) 333-338
27. Sandborn W.J., Hanauer S., Loftus Jr. E.V., Tremaine W.J., Kane S., Cohen R., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99 (2004) 1984-1989
28. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
29. Baidoo L., and Lichtenstein G.R. What next after infliximab?. Am J Gastroenterol 100 (2005) 80-83
30. Zeltser R., Valle L., Tanck C., Holyst M.M., Ritchlin C., and Gaspari A.A. Clinical, histological and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 137 (2001) 893-899
31. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
32. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005) 1304-1312
33. Gonzalez-Lopez M.A., Martinez-Taboada V.M., Gonzalez-Vela M.C., Blanco R., Fernandez-Llaca H., and Rodriguez-Valverde V. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 32 (2007) 672-674
34. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63 (2004) 508-516
35. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
36. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., and Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52 (2005) 2513-2518
37. Thurber M., Feasel A., Stroehlein J., and Hymes S.R. Pustular psoriasis induced by infliximab. J Drugs Dermatol 3 (2004) 439-440
38. Flendrie M., Vissers W.H., Creemers M.C., de Jong E.M., van de Kerkhof P.C., and van Riel P.L. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7 (2005) R666-R676
39. Pirard D., Arco D., Debrouckere V., and Heenen M. Anti-tumor necrosis factor-alpha induced psoriasiform eruptions: three further cases and current overview. Dermatology 231 (2006) 182-186
40. Aslanidis S., Pyrpasopoulou A., Leontsini M., and Zanboulis C. Anti-TNF-alpha-induced psoriasis: case report of an unusual adverse event. Int J Dermatol 45 (2006) 982-983
41. Passarini B., Infusino S.D., Barbieri E., Varotti E., Gionchetti P., Rizzello F., et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology 215 (2007) 295-300
42. Takahashi H., Hashimoto Y., Ishida-Yamamoto A., Ashida T., Kohgo Y., and Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol 34 (2007) 468-472
43. Wollina U., Hansel G., Koch A., Schönlebe J., Köstler E., and Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9 (2008) 1-14
44. Severs G.A., Lawlor T.H., Purcell S.M., Adler D.J., and Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis 80 (2007) 231-237
45. Lee H.H., Song I.H., Friedrich M., Gauliard A., Detert J., Röwert J., et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156 (2007) 486-491
46. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2008 Apr 2) [Epub ahead of print]
47. Verea M.M., Del Pozo J., Yebra-Pimentel M.T., Porta A., and Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 38 (2004) 54-57
48. Seneschal J., Lepreux S., Bouyssou-Gauthier M.L., Heliot-Hosten I., Economou A., Dehais J., et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm Venereol 87 (2007) 77-80
49. Seneschal J., Lepreux S., Milpied B., Schaeverbeke T., and Taieb A. Psoriasiform eruptions during anti-TNF-a treatment: psoriasis or not?. Arch Dermatol 143 (2007) 1593-1595
50. Thielen A.M., Barde C., Janer V., Borradori L., and Saurat J.H. Reiter syndrome triggered by adalimumab (Humira) and leflunomide (Arava) in a patient with ankylosing spondylarthropathy and Crohn disease. Br J Dermatol 156 (2007) 163-201
51. Wright R.C. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 49 (2003) 160-161
52. Chan J.L., Davis-Reed L., and Kimball A.B. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 3 (2004) 315-318
53. Vestergaard C., Deleuran M., and Kragballe K. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol 21 (2007) 1272-1274
54. Mangge H., Gindl S., Kenzian H., and Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol 30 (2003) 2506-2507
55. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343 (2000) 1594-1602
56. Garrison L., and McDonnell N. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 58 Suppl 1 (1999) 165-169
57. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., and Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients, following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43 (2000) 2383-2390
58. Eriksson C., Engstrand S., Sundqvist K.G., and Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64 (2005) 403-407
59. De Rycke L., Kruithof E., Van Damme N., Hoffman I.E., Van den Bossche N., Van den Bosch F., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48 (2003) 1015-1023
60. De Rycke L., Baeten D., Kruithof E., Van Den Bosch F., Veys E.M., and De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52 (2005) 2192-2201
61. Atzeni F., Turiel M., Capsoni F., Doria A., Meroni P., and Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 1051 (2005) 559-569
62. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized double blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
63. Poulalhon N., Begon E., Lebbe C., Liote F., Lahfa M., Bengoufa D., et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 156 (2007) 329-336
64. Klapman J.B., Ene-Stroescu D., Becker M.A., and Hanauer S.B. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9 (2003) 176-178
65. Sarzi-Puttini P., Atzeni F., Capsoni F., Lubrano E., and Doria A. Drug-induced lupus erythematosus. Autoimmunity 38 (2005) 507-518
66. Cairns A.P., Duncan M.K., Hinder A.E., and Taggart A.J. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 61 (2002) 1031-1032
67. Patel T., and Gordon K.B. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 17 (2004) 427-431
68. De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7 (2005) R545-R551
69. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
70. Stratigos A.J., Antoniou C., Stamathioudaki S., Avgerinou G., Tsega A., and Katsambas A.D. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol 29 (2004) 150-153
71. Brion P.H., Mittal-Henkle A., and Kalunian K.C. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 131 (1999) 634
72. Misery L., Perrot J.L., Gentil-Perret A., Pallot-Prades B., Cambazard F., and Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 146 (2002) 334-335
73. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86 4 (2007) 242-251
74. Srivastava M.D., Alexander F., and Tuthill R.J. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 61 (2005) 329-336
75. Mohan N., Edwards E.T., Cupps T.R., Slifman N., Lee J.H., Siegel J.N., et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31 (2004) 1955-1958
76. Devos S.A., Van Den Bossche N., De Vos M., and Naeyaert J.M. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206 (2003) 388-390
77. Kavanaugh A. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 27 (2000) 841-850
78. Lebas D., Staumont-Salle D., Solau-Gervais E., Flipo R.M., and Delaporte E. [Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases.]. Ann Dermatol Venereol 134 (2007) 337-342 French
79. McCain M.E., Quinet R.J., and Davis W.E. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 41 (2002) 116-117
80. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., and Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community-based cohort of patients with rheumatoid arthritis. J Rheumatol 29 (2002) 62-67
81. Wang L.C., Medenica M.M., Shea C.R., and Busbey S. Infliximab-induced eczematid-like purpura of Doukas and Kapetanakis. J Am Acad Dermatol 49 (2003) 157-158
82. Lee A., Kasama R., Evangelisto A., Elfendein B., and Falasca G. Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 12 (2006) 249-251
83. Vergara G., Silvestre J.F., Betlloch I., Vella P., Albares M.P., and Pascual J.C. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 138 (2002) 1258-1259
84. Beuthien W., Mellinghoff H.-U., and von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 50 (2004) 1690-1692
85. Graves J.E., Nunley K., and Heffernan M.P. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept. J Am Acad Dermatol 56 (2007) e55-e79
86. Badgwell C., and Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 56 (2007) 69-83
87. Callejas-Rubio J.L., Ortego-Centeno N., Lopez-Perez L., and Benticuaga M.N. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25 (2006) 596-597
88. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 (2003) 177-185
89. González-López M.A., Blanco R., González-Vela M.C., Fernández-Llaca H., and Rodríguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55 (2006) 817-820
90. Peno-Green L., Lluberas G., Kingsley T., and Brantley S. Lung injury linked to etanercept therapy. Chest 122 (2002) 1858-1860
91. Bremner R., Simpson E., White C.R., Morrison L., and Deodhar A. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum 34 (2004) 610-616
92. Deng A., Harvey V., Sina B., Strobel D., Badros A., Junkins-Hopkins J.M., et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor α inhibitors. Arch Dermatol 142 (2006) 198-202
93. Kreuter A., Gambichler T., and Altmeyer P. Infliximab therapy for interstitial granulomatous dermatitis. J Eur Acad Dermatol Venereol 21 (2007) 251-252
94. Voulgari P.V., Markatseli T.E., Exarchou S.A., Zioga A., and Drosos A.A. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 67 (2008) 567-570
95. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., and Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002) 2287-2293
96. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
97. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 56 (2007) 1125-1133
98. St Clair W.E., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
99. Salliot C., Gossec L., Ruyssen-Witrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 46 (2007) 327-334
100. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., and Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
101. Schneeweiss S., Setoguchi S., Weinblatt M.E., Katz J.N., Avorn J., Sax P.E., et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56 (2007) 1754-1764
102. Alonso-Ruiz A., Pijoan J.I., Ansuategui E., Urkaregi A., Calabozo M., and Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9 (2008) 52
103. Brimhall A.K., King L.N., Licciardone J.C., Jacobe H., and Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 159 (2008) 274-285
104. Gottlieb A.B., Leonardi C.L., Goffe B.S., Ortonne J.P., van der Kerkhof P.C., Zitnik R., et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 54 (2006) S92-100
105. Chan A.T., Cleeve V., and Daymond T.J. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 78 (2002) 47-48
106. Lowther A.L., Somani A.K., Camouse M., Florentino F.T., and Somach S.C. Invasive Trichophyton rubrum infection occurring with infliximab and long-term prednisone treatment. J Cutan Med Surg 11 (2007) 84-88
107. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
108. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
109. Genovese M.C., Barthon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
110. Baumgart D.C., and Dignass A.U. Shingles following infliximab infusion. Ann Rheum Dis 61 (2002) 661
111. Rallis E., Koumantaki-Mathioudaki E., Frangoulis E., Chatziolou E., and Katsambas A. Severe sporotrichoid fish tank granuloma following infliximab therapy. Am J Clin Dermatol 8 (2007) 385-388
112. Fallon J.C., Patchett S., Gulmann C., and Murphy G.M. Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab. Clin Exp Dermatol 33 (2008) 43-45
113. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
114. Smith C.H., Jackson K., and Bashir S.J. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 155 (2006) 160-169
115. Ahmad K., and Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 156 (2007) 1010-1014
116. Hoang K.J., and Burrus J. Localized cutaneous Cryptococcus albidus infection in a 14-year-old boy on etanercept therapy. Pediatr Dermatol 24 (2007) 285-288
117. Antoniou C., Kosmadaki M.G., Stratigos A.J., and Katsambas A.D. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 216 (2008) 364-365
118. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumor necrosis factor blockers do not increase overall tumor risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
119. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1703-1706
120. Wolfe F., and Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56 (2007) 1433-1439
121. Askling J., Baecklund E., Granath F., Geborek P., Fored M., Backlin C., et al. Anti-TNF therapy in RA and risk of malignant lymphomas. Relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis (2008May 8) [Epub ahead of print]
122. Gridley G., McLaughlin J.K., Ekbom A., Klareskog L., Adami H.O., Hacker D.G., et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85 (1993) 307-311
123. Hannuksela-Svahn A., Pukkala E., Laara E., Poikolainen K., and Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 114 (2000) 587-590
124. Williams G.M. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur J Cancer Prev 17 (2008) 169-177
125. Mahé E., Descamps V., Grossin M., Fraitag S., and Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 149 (2003) 170-173
126. Adams A.E., Zwicker J., Curiel C., Kadin M.E., Falchuk K.R., Drews R., et al. Aggressive cutaneous T-cell lymphomas after TNF-alpha blockade. J Am Acad Dermatol 51 (2004) 660-662
127. Berthelot C., Cather J., Jones D., and Duvic M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 6 (2006) 329-332
128. Sanli H., Ataman S., Akay B.N., Yilmaz A., Yildizlar D., and Gürgey E. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol 6 (2007) 834-836
129. Dauendorffer J.N., Rivet J., Allard A., and Bachelez H. Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis. Br J Dermatol 156 (2007) 742-743
130. Dalle S., Balme B., Berger F., Hayette S., and Thomas L. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol 153 (2005) 207-208
131. Smith K.J., and Skelton H.G. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 45 (2001) 953-956
132. Esser A.C., Abril A., Fayne S., and Doyle J.A. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 50 (2004) 75-77
133. Fryrear II R.S., Wiggins A.K., Sangueza O., and Yosipovitch G. Rapid onset of squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 51 (2004) 1026
134. Klareskog L., Gaubitz M., Rodriguez-Valverde V., Malaise M., Dougados M., and Wajdula J. Etanercept Study 301 Investigators. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 65 (2006) 1578-1584
135. Lebwohl M., Blum R., Berkowitz E., Kim D., Zitnik R., Osteen C., et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 141 (2005) 861-864
136. Moore R., Owens D., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor alpha are resistant to skin carcinogenesis. Nat Med 5 (1999) 828-831
137. Starcher B. Role for tumor necrosis factor-alpha receptors in ultraviolet-induced skin tumors. Br J Dermatol 142 (2000) 1140-1147
138. Chakravarty E.F., Michaud K., and Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32 (2005) 2130-2135
139. Tyring S., Gordon K.B., Poulin Y., Langley R.G., Gottlieb A.B., Dunn M., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143 (2007) 719-726
140. Marcil I., and Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358 (2001) 1042-1045
141. Euvrard S., Kanitakis J., and Claudy A. Skin cancers after organ transplantation. N Engl J Med 348 (2003) 1681-1691
142. Hollenbeak C.S., Todd M.M., Billingsley E.M., Harper G., Dyer A.M., and Lengerich E.J. Increased incidence of melanoma in renal transplantation recipients. Cancer 104 (2005) 1962-1967
143. Fulchiero Jr. G.J., Salvaggio H., Drabick J.J., Staveley-O'Carroll K., Billingsley E.M., Marks J.G., et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 56 (2007) S65-S67
144. Bovenschen H.J., Tjioe M., Vermaat H., de Hoop D., Witteman B.M., Janssens R.W., et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 154 (2006) 880-884
145. Alaibac M., Piaserico S., Rossi C.R., Foletto M., Zacchello G., Carli P., et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol 49 (2003) 1020-1022
146. Sfikakis P.P., and Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 15 (2003) 380-386
147. Nash P., Mease P.J., Braun J., and van der Heijde D. Seronegative spondyloarthropathies: to lump or split?. Ann Rheum Dis 64 (2005) 9-13
148. Flier J., Boorsma D.M., van Beek P.J., Nieboer C., Stoof T.J., and Willemze R. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194 (2001) 398-405
149. Aeberli D., Seitz M., Juni P., and Villiger P.M. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-a inhibitors. Rheumatology (Oxford) 44 (2005) 172-175
150. Gordon K.B., Bonish B.K., Patel T., Leonardi C.L., and Nickoloff B.J. The tumor necrosis factor-a inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 153 (2005) 945-953
151. Theofilopoulos A.N., and Lawson B.R. Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 58 (1999) 149-155
152. Via C.S., Shustov A., Rus V., Lang T., Nguyen P., and Finkelman F.D. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167 (2001) 6821-6826
153. Allanore Y., Sellam J., Batteux F., Job Deslandre C., Weill B., and Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 22 (2004) 756-758
154. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 53 (2000) 424-432
155. Ziegenhagen M.W., and Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 253 (2003) 18-30
156. Sweiss N.J., and Baughman R.P. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: Slaying the dragon?. J Rheumatol 34 (2007) 2129-2131
157. Wallis R.S., and Ehlers S. Tumor necrosis factor and granulomas biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34 Suppl 1 (2005) 34-38
158. Bhatia A., and Kast R.E. Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease. J Rheumatol 34 (2007) 447-449
159. Fischer M., Fiedler E., Marsch W.C., and Wohlrab J. Antitumor necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146 (2002) 707-708
160. Hunger R.E., Hunziker T., Buettiker U., Braathen L.R., and Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 116 (2005) 923-924
161. Meiss F., Helmbold P., Meykadeh N., Gaber G., Marsch W., and Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 21 (2007) 717-719
162. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
163. Saurat J.H., Stingl G., Dubertret L., Papp K., Langley R.G., Ortonne J.P., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158 (2008) 558-566
164. Schmitt J., Zhang Z., Wozel G., Meurer M., and Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol (2008 Jul 4) [Epub ahead of print]